Anebulo reports Q3 FY2022 net loss $1.9M; Phase 2 trial fully enrolled

Anebulo Pharmaceuticals, Inc.

Net loss of $1.9M ($0.08/share) for Q3 FY2022 vs $0.6M ($0.68/share) year ago.
Operating expenses rose to $1.9M from $0.6M in prior year period.
Cash and cash equivalents totaled $16.5M as of March 31, 2022.
Completed enrollment of 60 subjects in Part A of Phase 2 trial for ANEB-001; top-line data expected by June 30, 2022.
Company scheduled to present at four investor conferences and a cannabinoid symposium in May-June 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.